KLRA — Kailera Therapeutics, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 2096997 ·
Last close
$18.89
Market Cap
$2.45B
52W High
$28.23
52W Low
$18.69
ADV30
444,833
Next earnings
2026-08-07
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -84,660,000 -78,865,000 624,756,000 111,826,000 1,056,844,000
Mar 2025 0 -20,458,000 -17,983,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-86,511,000
Investing CF
$-31,591,000
Financing CF
$-2,980,000
CapEx
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.82
As of
2026-05-27

Balance + Analyst (yfinance extras)

Retained Earnings
$-447,533,000
Inventory
Receivables
$3,208,000
ST Investments
$407,348,000
EBIT TTM
$-105,118,000
Pretax Income TTM
$-96,848,000
Interest Exp TTM
Analysts
5

Annual Trend (SEC EDGAR, last 2y)

Revenues vs Net Income (last 2y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -158,340,000 -148,955,000 692,294,000 1,048,752,000 -120,210,000
Dec 2024 178,445,000 397,217,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-3.73

Peers — same industry

TickerNameMarket CapLastDaily %
VERA Vera Therapeutics, Inc. $2.46B $34.26
KNSA Kiniksa Pharmaceuticals International, plc $2.40B $51.89
RARE Ultragenyx Pharmaceutical Inc. $2.40B $24.35
SUPN SUPERNUS PHARMACEUTICALS, INC. $2.58B $44.41
IRON Disc Medicine, Inc. $2.60B $67.99

News headlines (Yahoo Finance, 1h cache)

‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic?
2026-06-15 04:48 · Yahoo
Parabilis Soared 58% in the Biggest Biotech IPO on Record. Is It Too Late to Buy the Stock?
2026-06-12 06:50 · Yahoo
How to Play PBLS Stock After the Parabilis IPO
2026-06-11 19:12 · Yahoo
Parabilis sets a record with a $670M biotech IPO
2026-06-10 11:06 · Yahoo
Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026
2026-06-05 23:32 · Yahoo
Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-28 20:05 · Yahoo
Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates
2026-05-26 20:02 · Yahoo
This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst
2026-05-13 18:43 · Yahoo
Hengrui Pharma and Kailera Therapeutics Announce Clinical Data Presentations at the American Diabetes Association 86th Scientific Sessions
2026-05-13 11:30 · Yahoo
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity
2026-05-12 20:26 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.